Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARTA: FOLFOX+Bevacizumab +/- Irinotecan in mCRC
NCT01321957Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- May 2011
- Primary completion
- Sep 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Martin Luther University Halle-Wittenberg. Started May 2011; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01321957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01321957.